Company intelligence / Profile preview

ErgoNex Pharma

Appenzell, Appenzell Innerrhoden, Switzerland

Ownership: Private
Development stage: Other

Overview

Terguride showed strong anti-serotoninergic activity and reached Phase 2 trial for pulmonary arterial hypertension; phase 2 proof-of-concept trials took place for PAH and fibromyalgia but further development was transferred to Pfizer for PAH.

Therapeutic areas: EndocrinologyRheumatologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

terguride

Unknown

Partnerships

Pfizer

Beyond the preview

Go deeper on ErgoNex Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ErgoNex Pharma.

Explore the full profile